Blog December 2, 2020
Final FDA Guidance on "Low Risk Wellness" Products Adopts Novel Approach for Exempting Devices From Regulation
- Person title
On July 29, 2016, the FDA released a final guidance on "General Wellness: Policy for Low Risk Devices," approximately 18 months after first proposing a novel rationale for not regulating what might otherwise be considered medical devices.
The guidance specifies that products "likely" won't be regulated as medical devices if (1) they are "low risk" (i.e. are not implanted or invasive or may pose a risk if specific regulatory controls are not applied such as for laser products) and (2) are intended only for "general wellness" use.
There are two broad categories of "general wellness" products. First are those that relate to maintaining or encouraging a general state of health or a healthy activity that do not refer to any specific disease or condition. The FDA enumerated seven specific areas that are apparently exhaustive and not merely examples of this category, namely: (1) weight management; (2) physical fitness/recreation; (3) relaxation or stress management; (4) mental acuity; (5) self-esteem; (6) sleep management; and (7) sexual function. Examples of such a product include a pulse rate monitor for use during exercise and an exfoliator to make skin smoother and softer.
The second category of "general wellness" products are those that are intended to promote, track, and/or encourage choices which, as part of a healthy lifestyle, may help to either (1) reduce the risk of certain chronic diseases or conditions or (2) live well with certain chronic diseases or conditions. Such wellness claims may only be made where it is "well understood" that healthy lifestyle choices may reduce the risk or impact of a chronic disease or conditions, such as may be evidenced by peer-reviewed scientific publications or official statements from healthcare professional organizations. Examples of such a product include a mobile app that reminds users to minimize exposure to the sun (which may reduce the risk of skin cancer) and a mobile app that monitors and records workout activity to maintain good cardiovascular health.
The FDA's approach for this second category is similar to the agency's regulation of "structure/function" claims for dietary supplements, which must be substantiated with valid scientific evidence but do not require prior FDA approval. Such claims typically refer to maintaining healthy structure or function of the body or general well-being. Thus, reference to the FDA's dietary supplement regulations may help to inform how the agency will implement the new "general wellness" policy for low risk devices.
The final guidance is available here.
The opinions expressed are those of the authors on the date noted above and do not necessarily reflect the views of Fish & Richardson P.C., any other of its lawyers, its clients, or any of its or their respective affiliates. This post is for general information purposes only and is not intended to be and should not be taken as legal advice. No attorney-client relationship is formed.
Blog December 9, 2019
Blog July 26, 2019
Heightened Scrutiny of Specimens of Use at U.S. Trademark Office
Blog July 3, 2019
New Rule Requires Foreign-Domiciled Trademark Applicants, Registrants, and Parties at TTAB to Be Represented by U.S. Attorney
Blog April 2, 2018
USPTO Pilot Program Regarding Specimen Authenticity
Blog July 5, 2017
U.S. Trademark Office Clarifies Filing Deadlines for Resurrecting Dead Applications and Registrations
Blog June 8, 2017
Even GOOGLE Can Google After All
Blog May 19, 2017
What Does The "In" in "Incontestable" Mean?
Blog February 7, 2017
U.S. Trademark Office Sharpens Machete for Pruning Deadwood
Blog February 3, 2017
FDA Final Guidance on Nonproprietary Names of Biological Products
Article March 8, 2023
Senior Principal Terry Mahn Authors Medical Device + Diagnostic Industry Article "This Company's False Compliance With CISPR 11 Resulted in a $12 Million FCA...
Article February 17, 2023
Principals Patrick Darno and Peter Fasse Author "Patent Strategies for Protecting Bioinformatics Inventions" for IAM
Article February 3, 2023
Fish & Richardson Attorneys Author IAM Article "Neglect Begets Opportunity in Femtech IP"
Blog January 17, 2023
Biosimilars 2022 Year in Review
Article October 20, 2022
Life Sciences Entrepreneur Sourcebook | Intellectual Property: What It Is and Why You Should Care
Blog September 15, 2022
What to Know About the USPTO's Duty of Candor Guidance Regarding FDA Submissions
Blog January 11, 2022
Biosimilars 2021 Year in Review
Blog December 2, 2020
IP and Cannabis: The Current Landscape
Blog August 8, 2019
5G Developments: From Rollout to Regulation
Article April 20, 2017